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ABSTRACT
Mutations in the gene encoding LRRK2 (leucine-rich repeat
kinase 2) were first identified in 2004 and have since been
shown to be the single most common cause of inherited
Parkinson’s disease. The protein is a large GTP-regulated
serine/threonine kinase that additionally contains several
protein–protein interaction domains. In the present review,
we discuss three important, but unresolved, questions
concerning LRRK2. We first ask: what is the normal
function of LRRK2? Related to this, we discuss the evidence
of LRRK2 activity as a GTPase and as a kinase and the
available data on protein–protein interactions. Next we
raise the question of how mutations affect LRRK2 function,
focusing on some slightly controversial results related to
the kinase activity of the protein in a variety of in vitro
systems. Finally, we discuss what the possible mechanisms
are for LRRK2-mediated neurotoxicity, in the context of
known activities of the protein.
Key words: GTPase, leucine-rich repeat kinase 2 (LRRK2),
Lewy body, neurotoxicity, Parkinson’s disease.
INTRODUCTION
In 2002, Funuyama et al. reported a new genetic linkage to
dominantly inherited PD (Parkinson’s disease) in a series of
families from the Sagamihara region of Japan. The original
evidence for a gene that caused PD was quite strong, but
there were some unusual features. For example, the disease
appeared to be dominant, but had decreased penetrance, i.e.
people who had inherited the chromosomal region that
tracked with disease did not always exhibit signs of PD. Also,
a few autopsies had been carried out previously on members
of the family and, whereas they had the expected
neurodegeneration in the substantia nigra that is typical of
PD and related diseases, they did not have Lewy bodies
(Hasegawa and Kowa, 1997). Lewy bodies are intracellular
neuronal aggregates made up in part of a protein a-
synuclein, and represent an important marker of typical,
sporadic forms of PD (for a discussion of the distinction
between Lewy body PD and Parkinsonism, see Hardy et al.,
2006). It was therefore not initially appreciated that this
family represented much more than an unusual, possibly even
private, disease that resembled PD.
However, less than 2 years later, not only had several
families been found worldwide that were linked to the same
chromosomal locus (Zimprich et al., 2004a), but also several
mutations were found in LRRK2 (leucine-rich repeat kinase 2)
(Paisa ´n-Ruı ´z et al., 2004; Zimprich et al., 2004a). By the next
year, LRRK2 mutations were shown to be relatively common,
occurring in 1–30% of all PD depending on the population
under study and whether familial PD is excluded or included
(reviewed in Cookson et al., 2005). This mutation frequency is
incredibly high for a disease that was considered to not be
genetic, as PD had been for many years. All mutations
reported to date are inherited in a dominant fashion, and
homozygotes have similar phenotypes and age at onset as
heterozygotes (Ishihara et al., 2007), indicating a true
dominant effect.
Importantly, the original Japanese family was also shown
to have a mutation in LRRK2, confirming the correct
identification of the gene (Funayama et al., 2005). In fact,
LRRK2 mutations in general are similar to those in the
original family. Penetrance is age-dependent, but still
incomplete (Hulihan et al., 2008; Latourelle et al., 2008), as
shown by mutation carriers surviving into their 80s without
developing symptoms of PD (Kay et al., 2005), far past the
typical onset of ,50 years of age. Also, examination of
additional family members from the Sagamihara kindred
revealed that some cases do have Lewy bodies (Hasegawa et
al., 2008). The variable pathological outcomes of LRRK2-
related disease was also emphasized by Zimprich et al.
(2004b) and confirmed in a number of other studies. Even
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commonly having (Ross et al., 2006) but occasionally lacking
(Gaig et al., 2007) Lewy bodies, even though the clinical
phenotypes are similar (reviewed in Cookson et al., 2008).
The data discussed so far tell us that LRRK2 mutations are a
surprisingly common cause of inherited PD. The decreased
penetrance of many LRRK2 mutations means that the genetic
contribution to lifetime risk of PD has probably been
underestimated in the past. Furthermore, the variable
pathological outcomes of LRRK2 mutations emphasizes that
the clinical course of disease is not entirely synonymous with
the underlying protein deposition, although it may be a
useful clue as to mechanism. Overall, LRRK2 mutations
represent a substantial advance in our understanding of
lifetime risk of PD, while slightly complicating our knowledge
of the relationship between symptoms and pathology.
Given this, how do inherited LRRK2 gene mutations
actually cause an adult onset neurodegenerative condition?
One way to address this critical problem is to consider the
intermediates between gene and phenotype, the altered
proteins that are produced by a mutant allele. In the present
review, we break this down into three apparently simple
questions, namely what is the normal function of LRRK2, how
do mutations change function and why might this altered
function result in PD? At this time, many of the more honest
answers to these questions are that we simply do not know,
but it is our hope that, by discussing each in turn, we might
be able to identify some of the key next steps for
understanding LRRK2 biology.
QUESTION ONE: WHAT DOES LRRK2
NORMALLY DO?
At the time of sequencing genes in the linkage region on
chromosome 12 that had been nominated to contain the
gene responsible, LRRK2 was not the most attractive
candidate. Not only was it poorly characterized, but also it
was rather large, requiring a significant investment of time to
sequence it. Overall, the full-length cDNA is 7.5 kb long,
encoding an ,280 kDa protein.
LRRK2 is named for its leucine-rich repeats and a kinase
domain. This arrangement is shared by one other protein,
LRRK1. In between these two regions is a GTPase sequence
called a ROC [for Ras of complex proteins (Bosgraaf and Van
Haastert, 2003)] domain and an adjacent COR (C-terminal of
ROC) domain. This pair of domains is characteristic of the
ROCO superfamily of proteins (Marin et al., 2008), which all
contain tandem ROC–COR domains, but do not all contain
kinase domains. In the human genome, there are four ROCO
proteins, of which three [LRRK1, LRRK2 and DAPK1 (death-
associated protein kinase 1)] are also kinases, but one
[MFHAS1 (malignant fibrous histiocytoma amplified sequence
1)] that is not (Lewis, 2009). In other species, there are
variable numbers of LRRK homologues; Drosophila melano-
gaster and Caenorhabditis elegans have a single LRRK
protein.
It has been misstated that the kinase domain of LRRK2 is
related to the MLKs (mixed lineage kinases), but analysis of all
kinase domains throughout the human genome suggests that
LRRK1 and LRRK2 form a small offshoot group of the RIPK
(receptor-interacting protein kinase) family of kinases, which
are somewhat similar to the IRAK (interleukin 1 receptor-
activated kinase) family and rather more distant from MLKs
(Manning et al., 2002). In contrast, the kinase domain of
DAPK1 is quite distinct from either LRRK homologue
(Manning et al., 2002). It has been proposed that, throughout
evolution of the LRRK genes, the kinase domain has been
acquired from different sources and is quite divergent in
sequence (Marin, 2006, 2008; Marin et al., 2008).
What makes LRRK2 different from LRRK1 is the N-
terminus, which is much longer in LRRK2. The motifs in this
region are not well annotated, but a number of repeat
sequences can be found that have a limited homology with
sequences found in the ankyrin family. Finally, near the C-
terminus of LRRK2 is a WD40 domain that probably forms a
b-propeller structure. The significance of the presence of
both ankyrin-like and leucine-rich repeats and a WD40
domain is that they are very likely to be protein–protein
interaction motifs and, with so many present, this indicates
that LRRK2 may act as a scaffold for several other proteins.
WD40 domains in other proteins can also interact with lipids
(e.g., McArdle and Hofmann, 2008), raising the possibility that
LRRK2 might be present at intracellular membranes. A
diagram of the domain structure of LRRK2 is shown in
Figure 1.
An added layer of complexity arises because LRRK2 self
interacts (Gloeckner et al., 2006) to form a dimer (Greggio et
al., 2008). Other ROCO family proteins also form dimers via
COR–COR interactions (Gotthardt et al., 2008); whether the
equivalent region of human LRRK2 has a similar structure is
unclear as there is some evidence of ROC–ROC interactions
(Deng et al., 2008). Regardless of the exact structural basis of
LRRK2 dimerization, the key motifs are similar enough in
LRRK1 to make heterodimers at least a possibility.
This information leads us to a model of a large protein with
a central catalytic GTPase/kinase region surrounded by
protein–protein and perhaps protein–membrane interaction
motifs, forming homo- and possibly hetero-dimers. To
understand function requires demonstration of whether the
kinase and ROC (GTPase) domains are enzymatically active.
For the kinase domain, the answer is a slightly tepid yes.
Several groups, including our own, have reported that full-
length LRRK2 or LRRK1 immunopurified from mammalian
cells has measurable kinase activity (West et al., 2005;
Gloeckner et al., 2006; Greggio et al., 2006; Korr et al., 2006;
MacLeod et al., 2006; Smith et al., 2006; Greggio et al., 2007;
Ito et al., 2007; Jaleel et al., 2007; Li et al., 2007; West et al.,
2007; Greggio et al., 2008; Imai et al., 2008). One small
concern is that the apparent activity of LRRK2 might arise
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several groups have used artificial kinase-dead variants that
have 10–20% of the activity of wild-type protein.
Furthermore, the LRRK2 kinase domain alone expressed in
Escherichia coli can be active (Luzon-Toro et al., 2007), as can
a larger fragment expressed in a baculovirus system (Anand et
al., 2009).
The major caveat here is that many of these studies used
autophosphorylation as a readout for kinase activity. Such
assays are commonly used to identify kinases because they
work, but that does not prove that the autophosphorylation
event is physiologically relevant. Sometimes autophos-
phorylation can be an important regulatory mechanism, e.g.
in the receptor tyrosine kinases, which autophosphorylate
when they form a dimer upon binding of their ligands. For
full-length LRRK2, we have shown that phosphorylation
occurs within each dimer molecule (Greggio et al., 2008),
although the isolated kinase domain can autophosphorylate
in trans (Luzon-Toro et al., 2007). But at this stage, the
autophosphorylation site(s) in LRRK2 have not been identified
and so they cannot yet be proven in vivo. There are two sites
(Ser
2032 and Thr
2035) in the activation loop that appear to
diminish kinase activity when mutated to alanine residues,
although these have not yet been proved to be authentically
due to autophosphorylation (Greggio et al., 2008). However,
LRRK2 is known to be active using autophosphorylation
assays when purified from transgenic mouse brain (Li et al.,
2007), where it is apparently more active than in other tissues
or in cultured cell lines. An alternative to autophosphoryla-
tion as an assay for kinase activity is to use generic substrates
such as MBP (myelin basic protein) (West et al., 2005;
Iaccarino et al., 2007; Luzon-Toro et al., 2007). Again, LRRK2
is modestly active in these assays, which suggests that LRRK2
is a serine/threonine-directed kinase, but does not lead to the
idea that MBP is a specific substrate for LRRK2, as many
serine/threonine kinases will mediate the same reaction.
Two heterologous LRRK2 substrates have been proposed:
moesin (Jaleel et al., 2007) and 4E-BP [eIF4E (eukaryotic
initiation factor 4E)-binding protein] (Imai et al., 2008).
Moesin is one of three proteins collectively named ERM for
the members ezrin/radixin/moesin. The major role of ERM
proteins is to anchor the cytoskeleton to the plasma
membrane, and thus influence processes in the cell related
to cytoskeletal dynamics at the cell surface such as
maintenance of neuronal growth cones (Paglini et al.,
1998). The C-terminal region of moesin, which contains an
actin-binding site, can interact with a FERM (4.1/ezrin/
radixin/moesin) domain in moesin’s N-terminal region in a
closed conformation. A shift to an open conformation is
required for binding to the cytoskeleton. The site on moesin
that is phosphorylated by LRRK2 (Thr
558, with a minor site at
Thr
526) is in the C-terminal domain and thus is normally
relatively inaccessible and, probably because of this, Jaleel et
al. (2007) found that pre-heating recombinant moesin to
.60˚C was required to see activity. Quantification suggested
that, even under these circumstances, phosphate was
incorporated into moesin at a ratio of ,10%, i.e. even here,
moesin is not a very efficient substrate. Short peptides
Figure 1 LRRK2 mutations and domains
Many variants in LRRK2 have been reported; some are clearly pathogenic, some are clearly not pathogenic and many are unclear. The
tests for pathogenicity are either segregation (blue box) within families or association with disease across populations (yellow box)
and mutations that pass either of these tests are placed in an approximate relationship to the linear sequence of the protein. Some
mutations, such as R1441H, are probably causal but segregation data is less clear and these are listed in the grey box. Finally, a large
number of polymorphic variants have been reported that are not likely to be pathogenic (white box). For the sake of clarity, not all
reported mutations are listed. Here, we show only non-synonymous amino-acid-changing variants that were found only in controls
(Paisa ´n-Ruı ´z et al., 2008) and thus are very unlikely to be related to disease. The ideogram in the lower part of the Figure shows
LRRK2 in a linear arrangement with each of the proposed domains labelled, from N- to C-termini; ANK, ankyrin-like repeats; LRR,
leucine-rich repeats; ROC, Ras of complex proteins, GTPase domain; COR, C-terminal of ROC domain; kinase; WD40, a b-propeller-
like domain made up of WD40 repeats. It should be noted that the clearly pathogenic variants cluster around the central enzymatic
region, whereas clearly polymorphic changes are distributed throughout the molecule.
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15containing the moesin Thr
558 motif, which would not be so
structurally restricted, also act as LRRK2 substrates (Jaleel et
al., 2007; Anand et al., 2009).
Overall, these data suggest that moesin and related
proteins are potential substrates for LRRK2. However,
LRRK2 has not yet been shown to be an authentic kinase
for moesin in vivo. The requirements to show this are
necessarily quite high, but showing (for example) that LRRK2-
knockout cells or animals have decreased moesin Thr
558
phosphorylation and that transfection with active full-length
LRRK2 increases the same event, or restores it in the case of
knockouts, would be one way forward. As discussed in the
next section, the pathogenic LRRK2 mutations may be helpful
in teasing apart some of these problems and assessing their
relevance for disease mechanisms.
Although the steps needed to support LRRK2 being an
authentic in vivo kinase for moesin are extensive, they are
feasible as shown by the work of Imai et al. (2008) on a
second proposed LRRK2 substrate. 4E-BP is an interactor of
e I F 4 E ,w h i c hi nt u r nb i n d st oc a p p e dm R N As p e c i e s ,
promoting their translation. Binding of 4E-BP to eIF4E
prevents the latter from being active, and therefore 4E-BP
is a repressor of protein translation. Oxidative stress and
other stimuli that have an impact on protein translation
affect phosphorylation of 4E-BP. Imai et al. (2008) have
proposed that LRRK2 modulates this system by phosphorylat-
ing 4E-BP. In mammalian cell culture, overexpression of
LRRK2 increases 4E-BP phosphorylation at a number of sites;
Imai et al. (2008) propose that LRRK2 first phosphorylates 4E-
BP at Thr
37/Thr
46, which then acts as a stimulus for further
phosphorylation by other kinases at secondary sites including
Ser
65/Thr
70. There is a modest decrease in phosphorylation of
4E-BP Thr
37/Thr
46 and Ser
65 when LRRK2 levels are knocked
down with RNAi (RNA interference). Furthermore, over-
expression of 4E-BP rescues the effects of LRRK mutants in
vivo using Drosophila models, which show increased
sensitivity to oxidative stress. Overall, these data are
supportive of 4E-BP being an authentic in vivo substrate
for LRRK2 or its Drosophila homologue, dLRRK. However, at
the time of writing, no independent confirmation of the
results of Imai et al. (2008) has been published, and details of
the phosphorylation reaction, such as how efficient phos-
phorylation of 4E-BP by LRRK2 is or whether this activity is
more efficient than autophosphorylation, are not yet
available.
Therefore several pieces of data support the idea that
LRRK2 is an active kinase, although the data to show that this
is true in vivo are more limited. What about the proposed
GTPase activity of the ROC domain? Again, evidence here is
mixed on whether this is enzymatically active, and some of
the details are important.
All published data support that full-length LRRK1 (Korr et
al., 2006; Greggio et al., 2007) and LRRK2 (Smith et al., 2006;
Guo et al., 2007; Ito et al., 2007; West et al., 2007) will bind
GTP at millimolar concentrations. However, data on whether
the protein is active as a GTPase are mixed. West et al. (2007)
reported that they were unable to detect GTPase activity in
full-length LRRK2 when expressed and immunopurified from
mammalian cells, whereas Ito et al. (2007) could only see
measurable activity if the protein was mutated to resemble
the more active small GTPase, Ras. In contrast, we (Lewis et
al., 2007) and others (Guo et al., 2007; Li et al., 2007) were
able to detect GTPase activity under similar circumstances.
Although small technical details may be critical for
identifying why the experiment can give different results
under different circumstances, the most likely explanation is
that the apparent GTPase activity of full-length LRRK2 is
quite weak. For example, we used an artificial mutant
(K1347A) that cannot bind GTP and therefore should have no
GTPase activity as a reference (Lewis et al., 2007) and found
that wild-type LRRK2 was only slightly more active than the
negative control.
In contrast, the ROC domain is much more active when
removed from the context of the full-length protein either
when expressed in E. coli (Deng et al., 2008) or in mammalian
cells (Li et al., 2007). The simplest explanation is that sequences
outside of the ROC domain modulate GTPase activity, perhaps
by physical interaction or by recruitment of other cellular
proteins. In prokaryotic ROC–COR proteins, dimerization is
critical for GTPaseactivity, and the CORdomainmayprovideat
least part of the dimer interface (Gotthardt et al., 2008). If this
is also true for human LRRK2, the COR domain would be a
positive regulator of GTPase activity, although not absolutely
required, and so inhibitory sequences would have to be present
outside of the ROC–COR bi-domain. Again, GTPase activity
could be regulated either by intramolecular interactions
intrinsic to LRRK2 in the context of the dimer, and/or by
recruitment of other proteins.
We therefore have two enzymatic domains, each of which
are at least potentially active. To complicate things further,
several groups have noted that binding of non-hydrolysable
GTP analogues {e.g. GTP[S] (guanosine 59-[c-thio]triphos-
phate) or p[NH]ppG (guanosine 59-[b,c-imido]triphosphate)}
stimulates the kinase activity of LRRK1 (Korr et al., 2006) and
LRRK2 (Smith et al., 2006; Ito et al., 2007; Li et al., 2007; West
et al., 2007). In the currently accepted model, GTP-bound
LRRK2 has a higher kinase activity than the GDP-bound
protein and thus GTPase activity would be important to
return LRRK2 kinase activity to basal levels. Whether this
predicted kinetic outcome of GTP binding and subsequent
hydrolysis occurs under physiological conditions has not yet
been proved. It should also be noted that the effect of GTP
binding is quite modest, increasing kinase activity ,2-fold,
and whether there is regulation of GTPase by kinase, for
example, is untested. It is possible that there are further
intramolecular events that influence GTPase activity, as has
been shown for the Dictyostelium ROCO kinase GbpC (van
Egmond et al., 2008). There are additional regulatory
sequences in LRRK2, as the C-terminal tail is required for
full kinase activity (Jaleel et al., 2007), whereas the N-
terminus of LRRK2 is inhibitory (Jaleel et al., 2007; Greggio et
al., 2008).
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portion of LRRK2 is probably the centrally important
regulatory region. What then is the function of the rest of
the protein? As discussed above, the various repeat regions
appear to be important for protein–protein interactions.
Several studies have identified candidate proteins bound to
LRRK2. The recessive Parkinsonism protein parkin was
reported by Smith et al. (2005) to interact with LRRK2.
Dachsel et al. (2007) reported several interactors for full-
length LRRK2 expressed in cells using MS approaches. Shin et
al. (2008) used yeast two-hybrid screening with the LRR
domain to identify Rab5b, a small GTPase involved in vesicle
endocytosis. Hsp90 (heat-shock protein 90) also binds to
LRRK2, perhaps in association with the co-chaperone Cdc37
(cell division cycle 37), and regulates its stability (Wang, L. et
al., 2008). LRRK2 is also reported to interact with a- and b-
tubulin, linking it to the cytoskeleton (Gandhi et al., 2008). In
most of these cases, binding to interactors was similar for
different LRRK2 variants, although mutant LRRK2 has
recently been reported to enhance binding to the apoptosis
protein FADD (Fas-associated death domain), which then
recruits caspase 8 (Ho et al., 2009). Therefore LRRK2 appears
to have a potentially large number of interacting partners,
with the caveat that most of these experiments have used
overexpressed LRRK2 rather than physiological levels of
protein, which appear to be quite low in most cell types. In
our hands, cells that appear to express higher levels of
endogenous LRRK2 such as transformed lymphoblastoid lines
(Melrose et al., 2007), have a high-molecular-mass (.1.2
MDa) complex including LRRK2, supporting their identifica-
tion using non-denaturing techniques (Greggio et al., 2008).
There is also some evidence that regions outside the ROC–
COR domain may contribute to the self-interaction of LRRK2
(Greggio et al., 2008).
Two things stand out about this list. First, several
interactors may give important clues about LRRK2 function.
For example, the Rab5a interaction is consistent with a role
for LRRK2 in mediating synaptic endocytosis (Shin et al.,
2008). This leads to the more important question of the
normal physiological role of LRRK2. As well as synaptic
endocytosis, LRRK2 has been proposed to have a role in
sorting of vesicles between axons and dendrites (Sakaguchi-
Nakashima et al., 2007). These two roles may be consistent
with localization of LRRK2 to vesicles in the brain (Biskup et
al., 2006), and possibly with localization to lipid rafts (Hatano
et al., 2007). LRRK2 expression also influences neurite
morphology in vitro and in vivo (MacLeod et al., 2006;
Plowey et al., 2008; Wang, L. et al., 2008). Finally, LRRK2 or
homologues in other species have been proposed to be
important in maintenance of neuronal viability in the
presence of oxidative stress (Imai et al., 2008; Liou et al.,
2008), although some studies have not identified a role in cell
survival (Wang, D. et al., 2008).
The second aspect of this list is that no interactors have
been identified that bind to the N-terminal region of LRRK2
before the LRR (leucine-rich repeat) domain. This is puzzling,
as the very large N-terminal region is the most divergent part
of the protein compared with LRRK1 and one might therefore
expect that any LRRK2-specific interactors might bind here
and be interesting for understanding function.
Overall, these data do not answer the question of the
normal function of LRRK2, but do give us the impression of a
complex modular protein. The central enzymatic ROC–COR-
kinase core has regulatory functions at least within the
context of the dimeric protein. Outside this are various
domains that may recruit other proteins into a complex,
making LRRK2 potentially a scaffolding protein, perhaps for
cell signalling pathways. Several recent papers have proposed
that LRRK2 or LRRK2 complexes act in ways that are
important for neuronal function, although one has to wonder
whether this is biased because of an expected role of LRRK2
in neurological disease. Although there is clearly much work
needed to resolve the question of the physiological role of
LRRK2, this outline should allow us to discuss how the
mutations in LRRK2 affect function of the protein.
QUESTION TWO: HOW DO MUTATIONS AFFECT
LRRK2 FUNCTION?
Before discussing how mutations affect function, we first
have to outline causation as it applies to genetics. For many
large genes, such as LRRK2, there are a large number of
variants along the 7500 nucleotides of the coding sequence
(Paisa ´n-Ruı ´z et al., 2008). Many of these are probably
innocuous, but some appear to be linked to disease and
distinguishing causal from innocuous variants is critical. From
a genetic perspective, there are two ways in which a variant
can be assigned as pathogenic. This can be either segregation,
where a phenotype is co-inherited with a disease-causing
mutation, or association, where, at a population level,
carrying a specific variant means an individual is at a higher
incidence of expressing a given phenotype. A mutation is any
variant that is rare (the classic definition is 1% frequency in a
population), whereas a polymorphism is a more frequent
variant.
For LRRK2, there are a number of mutations that show
clear evidence of segregation. The original Japanese family
carries an isoleucine to threonine substitution at position
2020 (I2020T) in the kinase domain (Funayama et al., 2005).
The common mutation found in many families worldwide is a
glycine to serine change at the adjacent residue (G2019S)
(Gilks et al., 2005; Goldwurm et al., 2005; Lesage et al., 2005;
Infante et al., 2006; Marongiu et al., 2006; Pankratz et al.,
2006; Papapetropoulos et al., 2006; Saunders-Pullman et al.,
2006; Williams-Gray et al., 2006; Zabetian et al., 2006a,
2006b; Ishihara et al., 2007; Orr-Urtreger et al., 2007;
Gorostidi et al., 2008; Healy et al., 2008; Latourelle et al.,
2008; Munhoz et al., 2008). In the ROC domain, an arginine at
residue 1441 can be replaced by a glycine residue (R1441G) in
Leucine-rich repeat kinase 2 mutations and Parkinson’s disease
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17several families in Spain and Portugal (Paisa ´n-Ruı ´z et al.,
2004; Mata et al., 2005; Ferreira et al., 2007; Bras et al., 2008;
Gorostidi et al., 2008) or by a cysteine residue (R1441C) in a
family from Nebraska (Zimprich et al., 2004b; Haugarvoll et
al., 2008). A tyrosine to cysteine mutation in the COR domain,
Y1699C, was reported in a family from the U.K. (Paisa ´n-Ruı ´z
et al., 2004) and in a family of German heritage with
members in Canada (Zimprich et al., 2004b).
Because there are multiple family members who carry the
mutation and develop PD, and in some cases there are several
families that may be more remotely related, we can be very
confident that five LRRK2 mutations are causal: R1441G/C,
Y199C, G2019S and I2020T. There are other mutations that
are less certainly pathogenic. Part of the problem is that PD is
a very common disease, with approx. 1% of people over the
age of 60 rising to 5% prevalence at the age of 80, so finding
PD in any given family is not surprising. If the phenotype
were extremely rare, such as having beetroot-coloured skin
and a lisp, we might be more confident. In many cases, the
families are relatively small and we cannot see generation-to-
generation transmission of the expected dominant trait,
perhaps due to missed diagnosis or incomplete penetrance.
Therefore some mutations are genuine variants and some are
also found in patients with PD, but will remain ambiguous, so
we have to rely sceptically on indirect evidence. Of the
reported variants, perhaps the only one that is very likely to
be pathogenic is R1441H (Zabetian et al., 2005; Spanaki et al.,
2006), because of the two other clearly pathogenic mutations
at the same residue that argue that this is a mutation hotspot
(Ross et al., 2008). Others are less certain; for example, I1371V
has been found in one case with a self-reported family
history of PD, but without clear evidence of segregation such
as an affected mutation-carrying parent (Paisa ´n-Ruı ´z et al.,
2005).
Then there are a few variants that are frequent enough to
be able to assess evidence for association with disease across
populations. For example, there is a glycine to arginine
substitution in the WD40 domain (G2385R) that is found only
in Asian populations, specifically in persons of Han descent.
Within these populations, G2385R is much more common in
PD cases compared with controls and thus shows associations
with lifetime risk of PD (Tan, 2006; Farrer et al., 2007; Chan et
al., 2008; Lin et al., 2008; Tan et al., 2009).
In summary, there are some mutations for which we have
strong evidence of segregation in the central enzymatic/
regulatory portion of LRRK2 and at least polymorphisms for
which we have evidence of association towards the C-
terminus. Interestingly, there are very few convincing muta-
tions towards the N-terminus of LRRK2 (Paisa ´n-Ruı ´z et al.,
2008), although the significance of this observation is unclear.
Working from the N- to the C-terminus, the first set of
convincing pathogenic mutations are those in the ROC
domain, R1441C/G and maybe R1441H. In those studies
where GTPase activity of LRRK2 could be measured, either
R1441C (Guo et al., 2007; Lewis et al., 2007) or R1441G (Li et
al., 2007) are associated with decreased GTPase activity
compared with wild-type proteins. One study (West et al.,
2007) proposed an increased GTPase activity, but actually
measured GTP binding and saw only small differences in this
parameter; in our own hands, R1441C and wild-type bind GTP
to the same extent (Lewis et al., 2007).
Interestingly, the effect of R1441C is less dramatic when
placed into the isolated ROC domain (Deng et al., 2008)
compared with the relatively strong effect (admittedly on a
weaker GTPase activity) in the full-length protein (Lewis et al.,
2007). One read of these data is that Arg
1441 has a key role in
interactions with other domains. This is slightly controversial,
as two different models have been proposed for where
Arg
1441 sits in the structure. Using the recombinant human
LRRK2 ROC domain isolated from other regions of the
protein, we have proposed that Arg
1441 stabilizes the
interface of a ROC–ROC dimer (Deng et al., 2008). In
contrast, the structure of a more complete ROC–COR protein
from the prokaryote Chlorobium tepidum suggests that the
equivalent residue is important in hydrophobic interactions
between ROC and COR domains (Gotthardt et al., 2008).
Resolution of these two models will require crystallization of
larger protein fragments of the human protein, as there are
several sequence differences around this region between the
two homologues. But what the two models both agree upon
is that Arg
1441 plays a small, but probably important, role in
the dimer interface and that substitutions at this region
decrease GTPase activity for the prokaryotic protein as much
as the eukaryotic version (Gotthardt et al., 2008). Although it
does not make the genetic evidence any stronger or weaker, it
should be noted that, under either model, R1441H would also
be defective in mediating the dimer formation, as arginine
specifically forms two hydrogen bonds with other residues in
the opposite chain, and no other side chain would be able to
do this. Furthermore, both models support pathogenicity of
the I1371V mutant, as the wild-type residue is in a
hydrophobic pocket again near the dimer interface.
Mutations in the COR domain itself have been less well
studied, probably because the assays to do this are less
obvious than for a GTPase homology domain. However, again
working from a prokaryotic homologue, Gotthardt et al.
(2008) have shown that the Y1699C equivalent (Y804C) also
decreases GTPase activity. As for the ROC mutations, the very
probable mechanism is that the substitution for the aromatic
residue disrupts a key element of the dimer interface, in this
case between the ROC and COR domains. Although an
equivalent experiment in human protein has not yet been
published, it is known that the ROC and COR domains of
LRRK2 interact physically (Deng et al., 2008), making the
prediction that Y1699C would have lower GTPase activity
owing to a lower stability dimer reasonable.
Therefore there is generally good agreement that ROC
mutations lower GTPase activity, with a nagging uncertainty
about the actual strength of activity, and a reasonable
prediction for COR mutations. Where the real controversy
starts is with the kinase domain. All studies published to date
have agreed that the effect of the G2019S kinase mutation is
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of assays (West et al., 2005; Greggio et al., 2006; MacLeod et
al., 2006; Smith et al., 2006; Guo et al., 2007; Jaleel et al.,
2007; Luzon-Toro et al., 2007; West et al., 2007; Covy and
Giasson, 2008; Imai et al., 2008; Anand et al., 2009). Data on
I2020T are more ambiguous, with some studies reporting
small, but significant, increases in activity (Gloeckner et al.,
2006; West et al., 2007; Imai et al., 2008), whereas others
report no effect (Luzon-Toro et al., 2007; Anand et al., 2009)
or even a slight decrease (Jaleel et al., 2007). Similar
uncertainty exists for the ROC and COR mutations, with
some studies reporting that all mutations increase activity up
to 2.5-fold (West et al., 2005; Smith et al., 2006; West et al.,
2007), whereas others suggesting that mutations of Arg
1441
and Tyr
1699 have only minor effects (Greggio et al., 2006;
MacLeod et al., 2006; Greggio et al., 2007; Jaleel et al., 2007;
Anand et al., 2009) and that similar mutations in LRRK1
slightly decrease activity (Korr et al., 2006). These data are
summarized in Figure 2, which we took from the original
references that reported quantitative effects of mutations
relative to wild-type LRRK2. These studies used several
different assays with a variety of constructs from full-length
through several N-terminally truncated versions to the
isolated kinase domain alone. The picture that emerges is
similar to the descriptive arguments above: only G2019S
consistently increases kinase activity, whereas other muta-
tions have inconsistent effects and generally only modestly
influence activity if there is a difference. No obvious pattern
emerges when considering different substrates, as the data
from different measures overlap (Figure 2).
Perhaps the place to start resolving some of these
apparently contradictory data is with the one change that
everyone agrees activates LRRK2, the common G2019S
mutation. How might this mutation work mechanistically
and/or structurally? Gly
2019 is part of a very highly conserved
motif, D(F/Y)G, where the aspartate residue (Asp
2017 in human
LRRK2) chelates a Mg
2+ ion that is required for cleavage of
the c-phosphate from ATP and thus for kinase activity. The
glycine residue (Gly
2019 in LRRK2) is absolutely invariant apart
from a few rare examples, which happen to be serine residues
(Jaleel et al., 2007). This residue marks the start of a
conformationally flexible region, the activation loop, which is
important for the control of kinase activity. For many kinases,
phosphorylation of this loop shifts its orientation relative to
the two lobes of the enzyme and thus allows or restricts
substrate access. The glycine residue is probably invariantly
conserved because the small side chain of this amino acid
allows maximum flexibility and thus motion of the activation
loop. We can speculate that a serine residue, with a
negatively charged hydroxy-containing side chain and less
conformational flexibility might ‘lock’ the kinase in a more
active conformation. Support for this idea comes from large-
scale sequencing of somatic mutations in cancer where
several equivalent glycine to serine changes were found in
kinases where increased activity is thought to be the
mechanism by which they are associated with excess cell
growth (Greenman et al., 2007). Also, substitution of alanine,
which also has a smaller side chain relative to serine, for this
glycine residue restores autophosphorylation to wild-type
levels (Luzon-Toro et al., 2007). One might also imagine that a
Figure 2 Effects of LRRK2 mutations on kinase activity
For this Figure, we took reported effects of LRRK2 mutations on kinase activity and expressed each relative to the wild-type LRRK2
reported in the same study, where the broken line across the graph51. Each study is given by first author and year and the different
symbols are colour-coded by substrate used in the assay; black, MBP; red, autophosphorylation; blue, LRRKtide peptide; purple,
4E-BP. Of all the mutations tested, the one that consistently shows an increased activity is G2019S in the kinase domain; all of the
others vary between experiments, and there is no clear pattern that relates to substrate used.
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19threonine residue at the adjacent amino acid within the
activation loop would have a similar effect, although this
would not explain why estimates of the effect of the I2020T
mutation are more variable compared with G2019S.
Mutations outside of the kinase domain are harder to
understand based on the above data. If the current model
that GTP binding to the ROC domain increases kinase activity
is correct, then decreased GTPase activity would mean that
the stimulatory effect of GTP binding would last longer for
ROC mutants, because the turnover of GTP to GDP would be
slowed. However, in the absence of GTP, as most of the above
kinase assays were performed, there should be no difference
in activity, and it seems likely ahead of time that non-
hydrolysable analogues would result in similar effects
irrespective of GTPase activity. Therefore the reason(s) kinase
activity measurements for mutations outside of the kinase
domain are variable between laboratories is unclear. Perhaps
there are small differences in the assay conditions that have a
large impact on the results, or perhaps our model of
regulation of kinase activity by GTP binding is flawed, but
the most likely interpretation is that the current assays need
refining. These issues are important to resolve, as, without
understanding how mutations work, it is hard to develop
clear ideas about mechanisms of neurodegeneration.
QUESTION THREE: WHY DO MUTATIONS IN
LRRK2 CAUSE NEURODEGENERATION?
So far, we have established that LRRK2 is an active enzyme, at
least in vitro and ex vivo, and that mutations either lower
GTPase activity or raise kinase activity, and we believe that
these two concepts are linked. However, none of this explains
why it is that LRRK2 mutations lead to neurodegeneration,
which is, in fact, a series of questions that are interlinked.
Clues to how LRRK2 might lead to neuronal death come
from where we started, from human genetics. It is worth
restating that the mode of inheritance is dominant with
incomplete penetrance and that homozygous cases have the
same phenotype as heterozygous. There are two likely ways in
which the LRRK2 protein could cause neuronal damage. The
mutations could result in a toxic gain-of-function, which
could be either misregulation of its normal function or
acquisition of a novel toxic function. However, it is also
possible that mutations are a loss of normal function: they
might, for example, interfere with the wild-type LRRK2
activity and act as a dominant-negative.
The tools to separate these possibilities are initially likely to
be based around experimental models. Several laboratories
have reported that high levels of overexpression of mutant
LRRK2 in primary cultured neurons or SH-SY5Y cells can lead
to cell death over a few days (Smith et al., 2005; Greggio et
al., 2006; MacLeod et al., 2006; Smith et al., 2006; Iaccarino
et al., 2007; West et al., 2007; Ho et al., 2009). Under similar
conditions, and at similar levels of expression, wild-type
mutant LRRK2 has only minor effects on basal cell viability,
although in one study, treating cells transfected with wild-
type LRRK2 with hydrogen peroxide resulted in dramatic cell
death (West et al., 2007). Overall, the consistent message is
that mutant LRRK2 can cause cell death, at least in the
context of cell culture models.
Also consistent between studies is the observation that
neurites are shorter after expression of mutant LRRK2
(MacLeod et al., 2006; Plowey et al., 2008; Wang, L. et al.,
2008). Whether this is related to toxicity or not is a little
unclear, but knockdown of LRRK2 causes a reciprocal increase
in neurite length and is not reported to result in cell death
(MacLeod et al., 2006). The mode of cell death related to
overexpression of mutant LRRK2 is reported to be apoptotic,
although evidence is mixed on whether this is a caspase 3
(Iaccarino et al., 2007) or caspase 8 (Ho et al., 2009)
-dependent pathway. Some evidence of TUNEL (terminal
deoxynucleotidyl transferase-mediated dUTP nick-end label-
ling) staining has been reported (Smith et al., 2005), although
this could be apoptosis or necrosis as DNA strand breaks can
be labelled by this technique in either mode of cell death.
Finally, in two models, there was evidence of autophagic
degradation of organelles, which might indicate a mixed
mode of cell death (MacLeod et al., 2006; Plowey et al., 2008).
What is interesting here, in the light of the discussion
about kinase activity above, is that all mutations are equally
toxic. Not only is the amount of cell death similar for all
mutations, but also estimates of cell death are also
remarkably similar across different models in different
laboratories. This leads logically to the question of whether
kinase activity is actually related to toxicity. We and others
have reported that pathogenic LRRK2 mutants that also were
engineered to be kinase-dead are much less toxic than
kinase-active versions (Greggio et al., 2006; Smith et al.,
2006). This suggests that kinase activity makes a substantial
contribution to cell death, at least in these cellular models.
This result would be simple to understand if all mutations
lead to increased kinase activity, but requires some discussion
if the effects of mutations on activity are variable. There are
several reasons that there might be an apparent dissociation
between the two measures. First, the kinase assays reported
to date may not capture all aspects of the function of the
enzyme. If, for example, there were a specific substrate for
the kinase activity of LRRK2 that mediates its toxic effects,
then measuring autophosphorylation may not capture this.
Perhaps more likely is the second possibility, that some
mutations work by regulating overall LRRK2 activity. Taking
the current model that GTP binding stimulates kinase activity
and the GTPase activity returns LRRK2 to basal levels, a
mutation such as R1441C that lowers GTPase activity would
only be revealed when LRRK2 is being regulated. Perhaps
consistent with this idea, Smith et al. (2006) were able to
show that introducing a K1347A mutation, which can bind
neither GDP nor GTP and has lower kinase activity, minimizes
the toxic effects of G2019S LRRK2. Measuring static kinase
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be required for toxicity. It should be noted that the hypothesis
could be reversed (kinase regulates GTPase) and the data
would still be consistent, but only if we thought that kinase
activity down-regulates GTPase activity. Another suggestion,
stated explicitly by Ho et al. (2009), is that mutations might
work in different ways to change a critical interactor that is
not necessarily a substrate. In their experiments, mutations
outside the kinase domain and I2020T increased binding to
FADD, but G2019S does not (Ho et al., 2009). However, FADD
interaction can be blocked by a kinase-inactivating mutation,
suggesting that an enhanced LRRK2–FADD interaction can be
achieved either by stronger physical interaction or by
enhancing kinase activity (Ho et al., 2009). In this view,
GTPase activity may not be especially crucial, or it may be that
GTP influences binding to FADD.
But there is also the possibility that kinase activity is really
not that important for the toxic effects of LRRK2 mutations.
Bear in mind that all of the above experiments rely on brief
overexpression of very high amounts of LRRK2 in cultured
cells, outside their native environment and potentially
exposed to additional stressors such as reactive oxygen
species, which can enhance LRRK2 toxicity (West et al., 2007).
An additional complication comes from the fact that some of
the hypothesis-testing mutations may alter LRRK2 stability.
For example, the GTP/GDP-binding-null K1347A mutation
used to test the requirement for GTP-dependent activation
(Smith et al., 2006) dramatically destabilizes LRRK2 protein, at
least in our experiments (Lewis et al., 2007), and are thus a
little more difficult to interpret if toxicity is concentration-
dependent.
For all of these reasons, the proposal that kinase activity
(or any other aspect of LRRK2 biology) is important in toxicity
should be considered as only a provisional hypothesis until it
can be tested rigorously in an intact brain. The first step to
doing this will probably be the development of animal
models, a few of which have been described recently. Loss of
dopamine cells is seen in transgenic Drosophila expressing
G2019S human LRRK2 (Liu et al., 2008). Similar phenomena
have been reported using dLRRK if the equivalent mutations
to Y1699C or I2020T are introduced (Imai et al., 2008).
Whether neuronal loss occurs in transgenic mice is currently
unclear, as only one BAC (bacterial artificial chromosome)-
transfected mouse has been reported and the phenotype of
the mouse was not discussed in that study (Li et al., 2007).
Neuronal loss was reported in rats where a fragment of
LRRK2 including the kinase domain was expressed transiently
in the rat cortex using viral vectors (MacLeod et al., 2006).
Clearly, in vivo models such as these will need to be
developed further before we can adequately assess whether
LRRK2 kinase activity is genuinely important in mediating
neuronal cell death.
The discussion of animal models highlights a question
discussed briefly above, that of whether the mutations work
as gain-of- (potentially novel) toxic function or as a
dominant-negative. One way to resolve this would be to
compare the phenotypes seen in knockout animals with those
resulting from overexpression. Here the data are mixed. In
Drosophila, although two groups found that high-level
overexpression of mutant LRRK2/LRRK causes cell loss (Lee
et al., 2007; Liu et al., 2008), another did not (Lee et al., 2007).
There are two published studies using different knockout
alleles reporting the LRRK is (Lee et al., 2007) or is not (Wang,
D. et al., 2008) required for dopamine neuron survival in the
same organism. Until these data are resolved, the loss-of-
function against gain-of-function argument cannot be
definitively answered. The detailed phenotype of LRRK2-
knockout mice has not been reported, although brains of
such animals have been used as controls for antibody-based
techniques (Biskup et al., 2007), so presumably they are viable.
Finally, it is worth discussing what the human pathology
may tell us about mechanisms involved in LRRK2-mediated
neurodegeneration. A more detailed tally of the various
pathologies found in different LRRK2 cases has been
published elsewhere (Cookson et al., 2008), but it will suffice
to say here that most cases are of Lewy-body-positive
Parkinsonism as discussed above. Because we know that one
of the major proteins found in Lewy bodies, a-synuclein, is
also a gene for PD when mutated (Polymeropoulos et al.,
1997; Kruger et al., 1998; Zarranz et al., 2004) or if expression
is increased without any sequence variants (Singleton et al.,
2003; Chartier-Harlin et al., 2004), a-synuclein fulfils the
requirements for a toxic agent in PD (Cookson, 2005). By
extension, if most cases of LRRK2 Parkinsonism have Lewy
bodies, it is possible that a-synuclein is a mediator of the
toxic damaged caused by mutant LRRK2. That some cases
with LRRK2 mutations do not have Lewy bodies complicates
the argument, but does not invalidate it if we accept the idea
that the deposition of proteins into inclusion bodies is not a
necessary part of the toxicity of aggregating proteins
(Cookson, 2005). LRRK2 cases can also have inclusions of
another potentially toxic protein, tau. If LRRK2 mutations can
express themselves as different pathologies, a logical
inference is that LRRK2 is ‘upstream’ in the neurodegenera-
tive process that can progress either via a-synuclein or tau. If
this were correct, then LRRK2 would be predicted to be an
accelerant of a-synuclein toxicity. How LRRK2 could
influence a-synuclein is unclear as, although a-synuclein is
phosphorylated, we have not been able to demonstrate any
direct phosphorylation with active LRRK2 (D.W. Miller, E.
Greggio and M.R. Cookson, unpublished data). However, the
idea of a relationship between the two dominant genes for
PD should at least be testable as animal models are
developed.
SUMMARY
Since the discovery of LRRK2 mutations in several independ-
ent families, a good deal of progress has been made in
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21understanding the protein. With some caveats, it seems likely
that the protein is active as both a GTPase and a kinase, and
that these two domains have some regulatory function.
Progress is being made on understanding interactions with
other proteins and on possible physiological roles of LRRK2.
How mutations work is still a little unclear, both from the
viewpoint of whether all mutations increase kinase activity
and how mutant proteins trigger toxicity. The next clear
challenges are to identify the cellular function of endogenous
LRRK2 and to develop robust animal models in which to test
ideas about pathogenesis that currently involve questions
such as whether kinase or other activities really are critical
for toxicity and the relationship to a-synuclein, another key
protein in PD pathogenesis. The final thing to be said is that
the reason for doing this is to find ways to prevent the
neuronal damage in PD and eventually to develop new
therapeutic modalities.
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